APTOSE BIOSCIENCES INC (APS.CA) Stock Price, Forecast & Analysis
Canada • Toronto Stock Exchange • TSX:APS • CA03835T4081
APS.CA Key Statistics, Chart & Performance
The current stock price of APS.CA is 2.23 CAD. In the past month the price increased by 5.69%. In the past year, price decreased by -71.41%.
APS.CA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to APS.CA. When comparing the yearly performance of all stocks, APS.CA is a bad performer in the overall market: 92.71% of all stocks are doing better.
APS.CA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APS.CA Forecast & Estimates
APS.CA Ownership
APS.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 580.449M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 375.908M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 139.775M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 68.396M | ||
| COV | COVALON TECHNOLOGIES LTD | 12.86 | 43.916M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.57 | 31.273M | ||
| RVX | RESVERLOGIX CORP | N/A | 30.171M | ||
| HEM | HEMOSTEMIX INC | N/A | 16.964M | ||
| MPH | MEDICURE INC | N/A | 12.006M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 10.716M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About APS.CA
Company Profile
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Company Info
APTOSE BIOSCIENCES INC
66 Wellington Street West, Suite 5300,, TD Bank Tower Box 48
TORONTO ONTARIO M2J 4R3 CA
CEO: William G. Rice
Employees: 13
Phone: 18589262730
APTOSE BIOSCIENCES INC / APS.CA FAQ
What does APTOSE BIOSCIENCES INC do?
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Can you provide the latest stock price for APTOSE BIOSCIENCES INC?
The current stock price of APS.CA is 2.23 CAD.
What is the dividend status of APTOSE BIOSCIENCES INC?
APS.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of APS stock?
APS.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is APTOSE BIOSCIENCES INC worth?
APTOSE BIOSCIENCES INC (APS.CA) has a market capitalization of 5.69M CAD. This makes APS.CA a Nano Cap stock.
Can you provide the ownership details for APS stock?
You can find the ownership structure of APTOSE BIOSCIENCES INC (APS.CA) on the Ownership tab.